Jurg Schifferli

Kantonsspital Basel, Medizinische Universitaetsklinik Basel, Switzerland

Jurg A Schifferli

Academic positions:
- Professor and head of the Division of Internal Medicine, Department of Medicine
- Head of the immunonephrology laboratory, Department Research, Basel University and School of Medicine
- Head of the Department of Medicine at the University Hospital Basel

All industry positions (in last five years):
None declared

Research interests:
Innate immunity (in particular complement, and neutrophil activation), autoimmune diseases, nephritis

Any other information:
Special appointment:
Member of Research Council of the Swiss National Foundation for Scientific Research

Member of the ECN (european complement network), the Swiss Society for Internal Medicine, -Nephrology, the British Society for Immunology

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Nephrology > Renal Immunology & Pathology (inc. Glomerular Diseases) (since 14 November 2005)

Links

http://www.dfbs.ch/index.html

All recent recommendations

• 8.8
  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
  Recommended by Kamyar Kalantar-Zadeh, Jurg Schifferli with Michael Mayr, Kenneth White with Emily G Farrow, Bradley Dixon, Csaba Kovesdy, Alan Yu with Jeanie Park, David Salant with Laurence H Beck Jr, Markus Ketteler
  
• 6.8
  Aliskiren combined with losartan in type 2 diabetes and nephropathy.
  Recommended by Csaba Kovesdy, Jurg Schifferli with Michael Mayr, Rajiv Agarwal, Mai Ots-Rosenberg, Robert Anderson
  
• 3.0
  HIF activation protects from acute kidney injury.
  Recommended by Jurg Schifferli with Michael Mayr
  
• 6.4
  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.
  Recommended by Neil Turner, Jurg Schifferli
  
• 6.0
  Natural history and outcome in systemic AA amyloidosis.
  Recommended by Jurg Schifferli
  
• 4.9
  Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
  Recommended by David Goldsmith, Asok Antony, Jurg Schifferli
  Dissent by Giuseppe Remuzzi
• 3.0
  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.
  Recommended by Jurg Schifferli
  
• 6.0
  Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
  Recommended by Jurg Schifferli